Annual Governance Meeting 17 December 2019 Mili Oncology - - PowerPoint PPT Presentation

Mili Oncology scientist Philadelphia, USA

Annual Governance Meeting

17 December 2019

Agenda

3

1. Welcome and Introductions 2. Chairman’s Report 3. Committee Reports − Audit & Risk Committee − Remuneration Committee − Corporate Responsibility Committee and Trust − Science Committee 4. Senior Independent Director’s Report 5. Questions 6. Discussion over tea and refreshments

Strictly private and confidential

Board

4

Jonathan Symonds Chairman Emma Walmsley CEO Iain Mackay CFO Dr Hal Barron CSO Vindi Banga Senior Independent Director Dr Laurie Glimcher Scientific & Medical Expert Lynn Elsenhans Corporate Responsibility Committee Chair Judy Lewent Audit & Risk Committee Chair & Financial Expert Urs Rohner Remuneration Committee Chair Jesse Goodman Science Committee Chair Scientific & Medical Expert Dr Vivienne Cox Workforce Engagement Director

Strictly private and confidential

Board Tenure, Skills & Diversity

5

91% 100% 91% 82% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%

Global US Europe EMAP % with experience Geographic Region

International Experience

1 2 3 4 5 6 7 8 9 10

Year(s) of Service

Tenure in years

55% 45%

Pharma Experience

55% 45%

Gender Diversity International Experience

Previous Pharma

experience

No previous Pharma experience

Female Male

Executive Director Non-Executive Director Strictly private and confidential

Chairman’s Report

− Why GSK? − Induction, Shareholder Meetings & Initial Impressions of GSK − Audit & Risk Committee Succession − External Board Review − Board Governance Architecture ahead of Separation − Update on behalf of the Workforce Engagement Director (WED) − R&D: Pennsylvania, US − Vaccines: Wavre, Belgium − Consumer Healthcare: New Jersey, US Jonathan Symonds - Chairman

6 Strictly private and confidential

Audit & Risk Committee

– Financial Reporting & Significant Issues – Effectiveness of our new Auditor & Implications of Audit Reform – Changes to our Sales Force Incentive Programme – Performance and Trust Priorities – Oversight of Transactions:

• Tesaro
• Consumer Healthcare Joint Venture with Pfizer

–

Internal Controls, Risk Management & Enterprise Risks

–

Cyber Security Key aspects of the Committee’s work this year:

7 Strictly private and confidential

Remuneration Committee

Key aspects of the Committee’s work this year: – 2020 Review of Remuneration policy

–

Alignment of LTI measures to delivery of Innovation priority

–

CEO Remuneration

–

Pension arrangements

–

Malus & Clawback provisions expanded

–

Loss of office payments policy – Wider workforce pay

8 Strictly private and confidential

Corporate Responsibility Committee & Trust

– Sustainable approach to access and affordability – US pricing – Science-led, focused global health strategy – Healthcare Professional (HCP) Engagement and Sales Force Incentives – Environment – Modern Employer – Stakeholder & ESG Insights Key aspects of the Committee’s work this year:

9 Strictly private and confidential

Science Committee

– R&D ‘Science x Technology x Culture’ Update – R&D Pipeline Update – Reviews of:

– Research – Development: Oncology & Non-Oncology – Vaccines

– R&D Transformation – Business Development and Strategic Partnerships Key aspects of the Committee’s work this year:

10 Strictly private and confidential

Senior Independent Director’s Report

– Chairman succession process – Perspectives on Board Dynamics – Role and contribution of Non Executive Directors Vindi Banga

11 Strictly private and confidential

Questions